Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Silexion Therapeutics Corp
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
silexion.comAI Executive Summary
AI-powered analysis of 8-K filing content
Silexion Therapeutics announced positive preclinical findings for SIL204, a novel therapy targeting KRAS-driven cancers with a significant mechanism for systemic uptake, marking a critical milestone in the company's oncology pipeline development.
Key Takeaways
SIL204 demonstrates a key mechanism for endogenous systemic uptake in KRAS-driven cancers based on preclinical findings
This advancement represents a critical milestone in Silexion's research and development pipeline for oncology therapeutics
2 more takeaways
Related Filings (1)
1 more filing from Silexion Therapeutics Corp in the last 90 days
Filing Overview
What This Means
Silexion Therapeutics Corp filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.